Patient-centered collaboration for regimen optimization
CAMBRIDGE, MA January 28, 2021 – Scipher Medicine, a precision immunology company matching patients with the most effective therapy, has joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms (NEWDIGS) initiative.
Scipher Medicine is the latest collaborator to join the Learning Ecosystems Accelerator for Patient-centered, Sustainable Innovation (LEAPS) project. In NEWDIGS’ unique safe haven environment, Scipher Medicine will collaborate with biopharmaceutical manufacturers, clinicians, regulators, payers, provider systems, patient advocacy groups and other health care stakeholders to catalyze collective evolution toward sustainable patient-centered biomedical innovation.
“We are eager to use this collaboration with NEWDIGS as an opportunity to partner with other professionals in the autoimmune disease space to innovate and learn,” said Alif Saleh, Chief Executive Officer of Scipher Medicine. “Our goal has always been to ensure that patients are prescribed drugs that work from day one. By working with other healthcare stakeholders, this collaboration will help deliver on this promise.”
“With its commitment to determining the right therapies for the right patients, Scipher Medicine is a natural fit for the LEAPS project as we advance system capabilities for regimen optimization, first for Rheumatoid Arthritis, and then for other disease areas,” said Gigi Hirsch, MD, executive director of NEWDIGS.
About Scipher Medicine
Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data. Leveraging our proprietary Network Medicine platform and artificial intelligence, we commercialize blood tests revealing a persons’ unique molecular disease signature and match such signature to the most effective therapy, ensuring optimal treatment from day one. The unprecedented amount of patient molecular data generated from our tests further drives the discovery and development of novel and more effective therapeutics. We partner with payers, providers, and pharma along the health care value chain to bring precision medicine to autoimmune diseases. Visit www.sciphermedicine.com and follow Scipher on Twitter, Facebook, and LinkedIn.
The NEW Drug Development ParadIGmS (NEWDIGS) Initiative at MIT is an international “think and do tank” dedicated to delivering more value faster to patients, in ways that work for all stakeholders. NEWDIGS designs, evaluates and initiates advancements that are too complex and cross-cutting to be addressed by a single organization or market sector. Its members include global leaders from patient advocacy, payer organizations, biopharmaceutical companies, regulatory agencies, clinical care, academic research and investment firms. For more information, visit http://newdigs.mit.edu.
MIT NEWDIGS Contact